Download Files:

Hu7691 free base

SKU T39733-1 mg Category Small Compound Brand: TargetMol

Price range: 469 CAD through 3,168 CAD

For Research Use Only (RUO). This product is sold strictly for laboratory research use. Not for human or veterinary consumption, therapeutic, or diagnostic use.For sale to research organizations and laboratories only; not for patients or for personal use.

Size

1 mg 10 mg 25 mg 5 mg 50 mg

Clear

Products Details

Product Description

– Hu7691 free base is an orally active, potent, and selective Akt inhibitor with anti-proliferative and neurogenic effects on various neuroblastoma cell lines. It inhibits Akt1, Akt2, and Akt3, and induces differentiation of neuroblastoma cells.

For Research Use Only (RUO). This product is sold strictly for laboratory research use only. Not for human or veterinary consumption, therapeutic, or diagnostic use. Any pharmacological, therapeutic, cosmetic, or biological effects described above are provided as research context only and do not represent intended or approved uses of this product.

Web ID

– T39733

Storage Temperature

– -20℃

Shipping

– Blue Ice

Molecular Formula

– C22H21F3N4O

References

– Jinxin Che, et al. Discovery of N-((3 S,4 S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1 H-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity. J Med Chem. 2021 Aug 26;64(16):1

CAS Number

– 2241232-43-7

Molecular Weight

– C22H21F3N4O

Compound Purity

– 0.9889

SMILES

– N(C(=O)C1=C(F)C=C(C=C1)C2=CC=NN2C)[C@H]3[C@@H](CCNC3)C4=CC(F)=C(F)C=C4

Pathway

– Cytoskeletal Signaling|||PI3K/Akt/mTOR signaling

Product type

– Small Compound

Booklet

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.